GENASCENCE
Clinical-stage biotechnology company developing life-changing gene therapy products for musculoskeletal diseases
GENASCENCE
Social Links:
Industry:
Biotechnology
Founded:
2017-01-01
Website Url:
http://www.genascence.com
Status:
Active
Total Funding:
10.5 M USD
Similar Organizations
Disarm Therapeutics
Disarm Therapeutics is a biotechnology company developing disease-modifying therapeutics for patients with axonal degeneration.
Global Blood Therapeutics
GBT is a clinical-stage biopharmaceutical company developing a therapy for sickle cell disease.
Theolytics
Theolytics is a pre-clinical stage biotechnology company developing next-generation oncolytic viral therapies.
Current Employees Featured
Founder
Investors List
Pacira Pharmaceuticals
Pacira Pharmaceuticals investment in Series A - Genascence
DeepWork Capital
DeepWork Capital investment in Series A - Genascence
University of Florida Research Foundation
University of Florida Research Foundation investment in Series A - Genascence
Polymerase Capital
Polymerase Capital investment in Series A - Genascence
Official Site Inspections
http://www.genascence.com
- Host name: 116.150.227.35.bc.googleusercontent.com
- IP address: 35.227.150.116
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Genascence"
Genascence - Crunchbase Company Profile & Funding
Genascence is a clinical-stage biotechnology company that is using gene therapy to revolutionize the treatment of common musculoskeletal diseases. The company intends to tackle one of the …See details»
Team - Genascence
Before joining Genascence, Marianne served as a Senior Director in Clinical Operations at a small biotech company that focused on mast and stem cells diseases. Prior to that, she spent 16 …See details»
Genascence Corporation - LinkedIn
Genascence is excited to share the U.S. Food and Drug Administration has granted Fast Track designation to GNSC-001, a potential first-in-class #genetherapy for the treatment of patients with # ...See details»
Science - Genascence
In the search to understand, prevent, and treat severe diseases, Genascence is committed to sharing information about clinical trials and making study results publicly accessible. We are …See details»
Genascence Company Profile 2024: Valuation, Funding …
Genascence was founded in 2017. Where is Genascence headquartered? Genascence is headquartered in Palo Alto, CA. What is the size of Genascence? Genascence has 7 total employees. What industry is Genascence in? …See details»
Genascence Company Profile - Craft
Genascence has 5 employees at their 1 location. See insights on Genascence including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Genascence - Contacts, Employees, Board Members, Advisors
Clinical-stage biotechnology company developing life-changing gene therapy products for musculoskeletal diseasesSee details»
Genascence Receives $11.6 Million Award From California Institute …
PALO ALTO, Calif., Feb. 23, 2023 /PRNewswire/ -- Genascence Corporation ("Genascence"), a clinical-stage biotechnology company revolutionizing the treatment of prevalent …See details»
Genascence: Pioneering Gene Therapy for Joint Diseases
Genascence, a start-up founded in 2017, aims to break that logjam, transforming the treatment of musculoskeletal (MSK) diseases with single-dose gene therapies. Its technology is based on …See details»
Genascence Announces First Close in Series A Financing led
PALO ALTO, Calif., May 10, 2022 /PRNewswire/ -- Genascence Corporation ("Genascence"), a clinical-stage biotechnology company revolutionizing the treatment of prevalent …See details»
Genascence Announces First Close in Series A Financing led by …
May 10, 2022 Genascence was founded in 2017, in Palo Alto, California, by a team of experts and industry leaders with deep experience and proven track record in the design, …See details»
Genascence Granted FDA Fast Track Designation for GNSC-001 in …
Nov 12, 2024 Genascence Corporation ("Genascence"), a clinical-stage biotechnology company revolutionizing the treatment of prevalent musculoskeletal diseases with gene therapy, today …See details»
Our Mission - Genascence
Osteoarthritis (OA) is a degenerative joint disease characterized by destruction of cartilage and structural changes in bone within a joint, such as the knee, which causes pain and disability.See details»
Genascence to Present at Biotech Showcase 2024 - Yahoo Finance
Dec 20, 2023 Genascence Corporation ("Genascence"), a clinical-stage biotechnology company revolutionizing the treatment of prevalent musculoskeletal diseases with gene therapy, today …See details»
Genascence Announces Initiation of Phase 1b Clinical Trial
Jan 3, 2024 Initial six-month data expected fourth quarter of 2024. PALO ALTO, Calif., Jan. 3, 2024 Genascence Corporation (“Genascence”), a clinical-stage biotechnology company …See details»
Genascence Granted FDA Fast Track Designation for GNSC-001 in …
PALO ALTO, Calif., Nov. 12, 2024 /PRNewswire/ -- Genascence Corporation ("Genascence"), a clinical-stage biotechnology company revolutionizing the treatment of prevalent …See details»
News & Publications - Genascence
May 17, 2022 Genascence Receives $11.6 Million Award From California Institute for Regenerative Medicine to Help Advance its Lead Gene Therapy Program in Knee …See details»
Genascence Announces Data From Phase 1 Clinical Trial on GNSC …
May 17, 2022 Genascence Announces Data From Phase 1 Clinical Trial on GNSC-001, Company's Lead Program in Osteoarthritis, Presented at American Society of Gene & Cell …See details»
Genascence is betting on gene therapy for osteoarthritis
Jan 20, 2023 Genascence is confident that a single administration of GNSC-001 could be effective because most gene therapies developed to date show that a single injection of an AV …See details»